AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7042068 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (same chemotherapy regimen + C. parvum 2 mg/M2 I.V. daily for 14 days before every third cycle and on days 7 and 14 of each cycle)
Number of subjects: 88
Study 31331579 — intervention group
Group type: EXPERIMENTAL
Intervention: Shiatsu therapy in addition to standard care
Number of subjects: 59
Study 31331579 — intervention group
Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 59
Study 30830386 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Loss (WL) intervention
Number of subjects: 0
Study 30830386 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol (PP) intervention
Number of subjects: 0
Study 26655432 — intervention group
Group type: EXPERIMENTAL
Intervention: ENCERT (Emotion Regulation Training)
Number of subjects: 244
Study 26655432 — intervention group
Group type: COMPARATOR
Intervention: Conventional CBT
Number of subjects: 244
Study 24886541 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir monotherapy (T arm)
Number of subjects: 8
Study 24886541 — intervention group
Group type: COMPARATOR
Intervention: Telaprevir in combination with peginterferon/ribavirin (TPR arm)
Number of subjects: 8
Study 24886541 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir monotherapy (T arm) and TPR arm
Number of subjects: 8
Study 23206461 — intervention group
Group type: EXPERIMENTAL
Intervention: Preincisional parecoxib (40 mg intravenously before skin incision)
Number of subjects: 0
Study 23206461 — intervention group
Group type: COMPARATOR
Intervention: Postincisional parecoxib (40 mg intravenously after skin incision)
Number of subjects: 0
Study 20227682 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone long-acting injectable (LAI)
Number of subjects: 559
Study 20227682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 559
Study 18586901 — intervention group
Group type: COMPARATOR
Intervention: Standard photodynamic therapy (sPDT) + 4 mg intravitreal triamcinolone (IVTA)
Number of subjects: 40
Study 18586901 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced fluence photodynamic therapy (rPDT) + 4 mg intravitreal triamcinolone (IVTA)
Number of subjects: 40
Study 16204871 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic method for fetal cardiac signal reconstruction using independent component analysis (ICA)
Number of subjects: 70
Study 16204871 — intervention group
Group type: COMPARATOR
Intervention: Classical procedure requiring manual classification of fetal components by an expert investigator
Number of subjects: 70
Study 12189542 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg m(‐2) i.v. day 1 and gemcitabine 1000 mg m(‐2) i.v. days 1, 8, and 15 of a 28 day cycle for a maximum of six cycles
Number of subjects: 53
Study 12189542 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and gemcitabine treatment
Number of subjects: 53
Study 10365742 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 48
Study 10365742 — intervention group
Group type: COMPARATOR
Intervention: No Heparin
Number of subjects: 48
Study 10365742 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin and No Heparin
Number of subjects: 48
Study 7621684 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG)‐releasing subdermal implants (Norplant)
Number of subjects: 0
Study 7621684 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG-IUD
Number of subjects: 0
Study 7621684 — intervention group
Group type: EXPERIMENTAL
Intervention: NET‐EN 200mg injectable contraceptives
Number of subjects: 0
Study 7621684 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined monthly injectable contraceptives (50mg NET‐EN and 5mg estradiol valerate)
Number of subjects: 0
Study 7621684 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined low‐dose oral pills (triphasic and monophasic)
Number of subjects: 0
Study 7621684 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper IUDs
Number of subjects: 0
Study 2137076 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg nebulized salbutamol followed by 0.5 mg ipratropium
Number of subjects: 117
Study 2137076 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium followed by salbutamol
Number of subjects: 117
Study 2137076 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs administered together followed by nebulized saline
Number of subjects: 117
Study 2137076 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium given after salbutamol
Number of subjects: 117
Study 2137076 — intervention group
Group type: COMPARATOR
Intervention: Combination of drugs
Number of subjects: 117
Study 7003572 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol 100 mg orally
Number of subjects: 30
Study 7003572 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine 25 mg orally
Number of subjects: 30
Study 7003572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30536589 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3342830 (single intravenous doses ranging from 250 to 6000 mg)
Number of subjects: 62
Study 30536589 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3342830 (repeat intravenous infusions 3 times a day)
Number of subjects: 62
Study 30536589 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3342830 (multiple doses)
Number of subjects: 62
Study 30536589 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 62
Study 30413184 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment of varlilumab plus rituximab
Number of subjects: 40
Study 27387752 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 months of follow-up at a primary care facility with clinical support from a telemedicine platform
Number of subjects: 280
Study 27387752 — intervention group
Group type: COMPARATOR
Intervention: 12 months of follow-up at the same clinic
Number of subjects: 280
Study 24680759 — intervention group
Group type: EXPERIMENTAL
Intervention: BioEnterics Intragastric Balloon (BIB)
Number of subjects: 1357
Study 24680759 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 1357
Study 22544225 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave ablation (MW)
Number of subjects: 42
Study 22544225 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation (RF)
Number of subjects: 42
Study 20381014 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery processing of worry
Number of subjects: 0
Study 20381014 — intervention group
Group type: COMPARATOR
Intervention: Verbal processing of worry
Number of subjects: 0
Study 18924648 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC/EFV regimen (1 pill once a day)
Number of subjects: 141
Study 15804873 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (DMI) treatment in combination with buprenorphine (BUP)
Number of subjects: 165
Study 15804873 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (DMI) treatment in combination with methadone (Meth)
Number of subjects: 165
Study 15804873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 12727155 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle exercise training
Number of subjects: 46
Study 12727155 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) of the legs
Number of subjects: 46
Study 12727155 — intervention group
Group type: COMPARATOR
Intervention: Bicycle exercise training and FES combined
Number of subjects: 46
Study 11108211 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural network prediction of LV mass
Number of subjects: 317
Study 11108211 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural network prediction of LVH
Number of subjects: 317
Study 8986585 — intervention group
Group type: EXPERIMENTAL
Intervention: Coculture with human oviductal cells for 24 hours before embryo transfer
Number of subjects: 181
Study 8986585 — intervention group
Group type: COMPARATOR
Intervention: Earles' balanced salt solution supplemented with 15% preovulatory serum (control)
Number of subjects: 181
Study 8986585 — intervention group
Group type: EXPERIMENTAL
Intervention: Coculture with human oviductal cells
Number of subjects: 181
Study 1575130 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnum/Magnarail system
Number of subjects: 100
Study 1575130 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnum/Magnarail system as a second tool after crossover
Number of subjects: 100
Study 1575130 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnum/Magnarail group
Number of subjects: 100
Study 1575130 — intervention group
Group type: COMPARATOR
Intervention: Conventional group
Number of subjects: 100
Study 3886710 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaprozin
Number of subjects: 12
Study 3886710 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 12
Study 30500116 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin (300 mg daily from days 20-41) with Bedaquiline (400 mg on days 1 and 29)
Number of subjects: 0
Study 30500116 — intervention group
Group type: COMPARATOR
Intervention: Rifampin (600 mg daily from days 20-41) with Bedaquiline (400 mg on days 1 and 29)
Number of subjects: 0
Study 28127206 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Snare Polypectomy (CSP)
Number of subjects: 208
Study 28127206 — intervention group
Group type: COMPARATOR
Intervention: Hot Forceps Biopsy (HFB)
Number of subjects: 208
Study 26775256 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde tibial tunnel drilling
Number of subjects: 43
Study 26775256 — intervention group
Group type: COMPARATOR
Intervention: Antegrade tibial tunnel drilling
Number of subjects: 43
Study 26775256 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibial tunnel diameter ≤8mm
Number of subjects: 43
Study 26775256 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibial tunnel diameter >8mm
Number of subjects: 43
Study 24612754 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative community-based care plus facility-based care
Number of subjects: 282
Study 24612754 — intervention group
Group type: COMPARATOR
Intervention: Facility-based care alone
Number of subjects: 282
Study 23090528 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual prenatal care for mild GDM (371 women)
Number of subjects: 1535
Study 23090528 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for mild GDM (397 women)
Number of subjects: 1535
Study 23090528 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose intolerance (767 women)
Number of subjects: 1535
Study 18946677 — intervention group
Group type: EXPERIMENTAL
Intervention: MeroGel (hyaluronan resorbable packing)
Number of subjects: 66
Study 18946677 — intervention group
Group type: COMPARATOR
Intervention: Standard non‐resorbable nasal dressing
Number of subjects: 66
Study 18946677 — intervention group
Group type: EXPERIMENTAL
Intervention: MeroGel
Number of subjects: 66
Study 17156141 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfate supplements
Number of subjects: 0
Study 17156141 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster intestinal transit
Number of subjects: 0
Study 17156141 — intervention group
Group type: COMPARATOR
Intervention: Loperamide
Number of subjects: 0
Study 17156141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17156141 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfate supplements with senna
Number of subjects: 0
Study 15860487 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 75 mg/m2 and etoposide 100 mg/m2 (arm A)
Number of subjects: 369
Study 15860487 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC=6 mg/ml min and paclitaxel 225 mg/m2 (arm B)
Number of subjects: 369
Study 11990269 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil by patient-controlled analgesia (PCA)
Number of subjects: 36
Study 11990269 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular meperidine
Number of subjects: 36
Study 10221068 — intervention group
Group type: EXPERIMENTAL
Intervention: bisoprolol 1.25 mg/day, progressively increased to a maximum of 10 mg/day
Number of subjects: 2647
Study 10221068 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2647
Study 8919833 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg i.v. 1 hour before induction of anaesthesia (Group A)
Number of subjects: 90
Study 8919833 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg i.v. 1 hour before end of surgery (Group B)
Number of subjects: 90
Study 8919833 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group C - control group)
Number of subjects: 90
Study 2195929 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin 100 IU every other day plus 1 g of elemental calcium daily
Number of subjects: 62
Study 2195929 — intervention group
Group type: COMPARATOR
Intervention: Calcium supplementation only
Number of subjects: 62
Study 514717 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrode temperature of 44.5 C
Number of subjects: 0
Study 514717 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrode temperatures ranging from 43.0 to 45.0 C
Number of subjects: 0
Study 514717 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous measurements from two electrodes with different temperatures
Number of subjects: 0
Study 31909809 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut diet (WD) [57-99 g/d walnuts, 7% SFAs, 16% PUFAs (2.7% ALA), 9% MUFAs]
Number of subjects: 34
Study 31909809 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut diet (WD)
Number of subjects: 34
Study 31909809 — intervention group
Group type: COMPARATOR
Intervention: Oleic acid replaces ALA diet (ORAD)
Number of subjects: 34
Study 31483451 — intervention group
Group type: EXPERIMENTAL
Intervention: IPSE (Individual Placement and Support with enhancements)
Number of subjects: 720
Study 31483451 — intervention group
Group type: COMPARATOR
Intervention: SAU (Service as Usual)
Number of subjects: 720
Study 31483451 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS (Individual Placement and Support)
Number of subjects: 720
Study 31483451 — intervention group
Group type: COMPARATOR
Intervention: IPS vs SAU
Number of subjects: 720
Study 31483451 — intervention group
Group type: COMPARATOR
Intervention: IPSE vs SAU
Number of subjects: 720
Study 28901889 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised breakfast (SB) approximately 1962 kJ
Number of subjects: 40
Study 28901889 — intervention group
Group type: COMPARATOR
Intervention: No breakfast (NB)
Number of subjects: 40
Study 26400925 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) injections
Number of subjects: 20
Study 26400925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 24666667 — intervention group
Group type: EXPERIMENTAL
Intervention: PCE
Number of subjects: 601
Study 24666667 — intervention group
Group type: EXPERIMENTAL
Intervention: PCC
Number of subjects: 601
Study 24666667 — intervention group
Group type: EXPERIMENTAL
Intervention: PCC + PCE
Number of subjects: 601
Study 24666667 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 601
Study 21181252 — intervention group
Group type: EXPERIMENTAL
Intervention: Single item measure (qualitative Likert-type responses)
Number of subjects: 53
Study 21181252 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-item measure (averaged responses across antiretrovirals)
Number of subjects: 53
Study 21181252 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall agreement between measures
Number of subjects: 53
Study 21181252 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-item measures
Number of subjects: 53
Study 19603474 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional meat intake (200 g pork fillet/day)
Number of subjects: 14
Study 19603474 — intervention group
Group type: COMPARATOR
Intervention: Omission of meat and meat products (NOM)
Number of subjects: 14
Study 17876463 — intervention group
Group type: EXPERIMENTAL
Intervention: Culling infected dogs
Number of subjects: 34
Study 17876463 — intervention group
Group type: EXPERIMENTAL
Intervention: Spraying houses and animal pens with insecticide
Number of subjects: 34
Study 17876463 — intervention group
Group type: EXPERIMENTAL
Intervention: Spraying houses and eliminating infected dogs
Number of subjects: 34
Study 17876463 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of spraying houses and animal pens, and eliminating infected dogs
Number of subjects: 34
Study 17876463 — intervention group
Group type: COMPARATOR
Intervention: Only spraying houses
Number of subjects: 34
Study 15341540 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA) and multidisciplinary intervention
Number of subjects: 739
Study 15341540 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 739
Study 12107516 — intervention group
Group type: EXPERIMENTAL
Intervention: SITA Fast (HSF)
Number of subjects: 76
Study 12107516 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendency Orientated Perimetry (TOP)
Number of subjects: 76
Study 9828797 — intervention group
Group type: EXPERIMENTAL
Intervention: Axially acquired, coronally reconstructed images
Number of subjects: 52
Study 9828797 — intervention group
Group type: COMPARATOR
Intervention: Coronal helical CT images
Number of subjects: 52
Study 7815703 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 4 mg
Number of subjects: 60
Study 7815703 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 2.5 mg
Number of subjects: 60
Study 7815703 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 0 mg
Number of subjects: 60
Study 2573336 — intervention group
Group type: EXPERIMENTAL
Intervention: Arousal manipulation (unrelated aversive event - shock)
Number of subjects: 40
Study 2573336 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed of fear-reduction
Number of subjects: 40
Study 6155338 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal vaccination with cold-adapted influenza A/HK/77 (H1N1) CR 35 recombinant virus
Number of subjects: 0
Study 31793486 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric handgrip exercise training at 30% maximum voluntary contraction for 2 min each day for 24 consecutive days combined with lifestyle modification
Number of subjects: 400
Study 31793486 — intervention group
Group type: COMPARATOR
Intervention: Control group with lifestyle modification only
Number of subjects: 400
Study 31793486 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric handgrip exercise training at 30% maximum voluntary contraction
Number of subjects: 400
Study 28213205 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS stimulation on
Number of subjects: 30
Study 28213205 — intervention group
Group type: COMPARATOR
Intervention: TENS stimulation off (control)
Number of subjects: 30
Study 25948064 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg/day for 6 weeks
Number of subjects: 167
Study 25948064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study 23949899 — intervention group
Group type: EXPERIMENTAL
Intervention: Mildronate injection
Number of subjects: 227
Study 23949899 — intervention group
Group type: COMPARATOR
Intervention: Cinepazide injection (active-control)
Number of subjects: 227
Study 21827439 — intervention group
Group type: EXPERIMENTAL
Intervention: Information form given before the pre-anaesthetic consultation
Number of subjects: 200
Study 21827439 — intervention group
Group type: COMPARATOR
Intervention: No information form (control group)
Number of subjects: 200
Study 19266829 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-MCT/LCT premixed with normal saline (Group A)
Number of subjects: 300
Study 19266829 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-MCT/LCT premixed with 20 mg lignocaine (Group B)
Number of subjects: 300
Study 19266829 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-LCT premixed with 20 mg lignocaine (Group C)
Number of subjects: 300
Study 18664154 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5-methyl aminolevulinate cream applied for 1 hour before red light illumination
Number of subjects: 10
Study 18664154 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5-methyl aminolevulinate cream applied for 3 hours before red light illumination
Number of subjects: 10
Study 18664154 — intervention group
Group type: COMPARATOR
Intervention: Control side (no treatment)
Number of subjects: 10
Study 18664154 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment sides
Number of subjects: 10
Study 15355485 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (100, 200, or 400 mg/day)
Number of subjects: 0
Study 15355485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15355485 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 0
Study 15355485 — intervention group
Group type: COMPARATOR
Intervention: Topiramate and Placebo
Number of subjects: 0
Study 11171823 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide 100 mg twice daily
Number of subjects: 36
Study 11171823 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg twice daily
Number of subjects: 36
Study 9051085 — intervention group
Group type: EXPERIMENTAL
Intervention: buffy coat‐depleted packed red cells
Number of subjects: 697
Study 9051085 — intervention group
Group type: EXPERIMENTAL
Intervention: white cell‐reduced (filtered) packed red cells
Number of subjects: 697
Study 9051085 — intervention group
Group type: COMPARATOR
Intervention: no transfusion
Number of subjects: 697
Study 8347121 — intervention group
Group type: EXPERIMENTAL
Intervention: Generation of random letters task
Number of subjects: 68
Study 8347121 — intervention group
Group type: EXPERIMENTAL
Intervention: Articulatory suppression task
Number of subjects: 68
Study 8347121 — intervention group
Group type: EXPERIMENTAL
Intervention: Visuo-spatial tasks
Number of subjects: 68
Study 8347121 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported worriers vs non-worriers
Number of subjects: 68
Study 2422778 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of PPS by intramuscular (I.M.) route (group I)
Number of subjects: 30
Study 2422778 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of PPS by intramuscular (I.M.) route (group II)
Number of subjects: 30
Study 2422778 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of PPS by subcutaneous (S.C.) route (group III)
Number of subjects: 30